DaVita Inc. has announced its financial and operating results for the first quarter ended March 31, 2025. The company reported consolidated revenues of $3.224 billion. Operating income for the quarter was $439 million. Diluted earnings per share $(EPS)$ stood at $2.00. In terms of cash flow, DaVita experienced an operating cash flow of $180 million, but free cash flow was negative at $(45) million. The company also repurchased 3.7 million shares of its common stock at an average price of $148.94 per share. In terms of U.S. dialysis metrics, DaVita reported a total of 7,040,519 dialysis treatments for the first quarter of 2025, averaging 91,793 treatments per day. This represents a per-day increase of 0.01% compared to the fourth quarter of 2024. However, there was a normalized non-acquired treatment growth decrease of 0.6% compared to the first quarter of 2024. DaVita's leadership emphasized the stability and consistency of their operating model, reaffirming their commitment to being the provider, employer, and partner of choice while returning value to shareholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.